Abbott Laboratories (ABT)
| Market Cap | 222.07B |
| Revenue (ttm) | 40.23B |
| Net Income (ttm) | 6.38B |
| Shares Out | 1.78B |
| EPS (ttm) | 4.03 |
| PE Ratio | 31.02 |
| Forward PE | 24.94 |
| Dividend | $1.80 (1.44%) |
| Ex-Dividend Date | Oct 14, 2021 |
| Volume | 4,984,034 |
| Open | 124.54 |
| Previous Close | 123.31 |
| Day's Range | 123.09 - 125.60 |
| 52-Week Range | 101.56 - 129.20 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 134.28 (+7.4%) |
| Est. Earnings Date | n/a |
About ABT
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidi...
Financial Performance
In 2020, ABT's revenue was $34.61 billion, an increase of 8.48% compared to the previous year's $31.90 billion. Earnings were $4.50 billion, an increase of 21.91%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 134.28, which is an increase of 7.38% from the latest price.
News
3 Things Investors Should Love About Abbott's Q3 Results
There was nothing but good news for Abbott in Q3.
Why Abbott Laboratories Shot Higher Today
All four of the company's divisions posted strong growth, but one in particular was a standout.
Is it too late to buy Abbott shares after raising FY2021 earnings guidance?
On Wednesday, Abbott Laboratories (NYSE:ABT) shares surged nearly 4% after announcing solid fiscal third-quarter results. The company reported its most recent quarterly revenue and earnings before marke...
Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up
Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
Just before Tuesday's close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company cited a robust slate of content including t...
Abbott (ABT) Q3 Earnings and Revenues Beat Estimates
Abbott (ABT) delivered earnings and revenue surprises of 52.17% and 15.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Abbott Shares Are Rising Today
Abbott Laboratories (NYSE: ABT) is trading higher Wednesday after the company announced better-than-expected third-quarter financial results and raised guidance. Abbott reported quarterly earnings of $...
Abbott's Q3 Profit Jumps 70% On Robust COVID-19 Test Sales
Abbott Laboratories (NYSE: ABT) reported a 70.5% rise in quarterly profit to $2.1 billion, helped by strength in its medical devices and diagnostics businesses due to a rebound in COVID-19 test sales am...
Abbott raises annual profit forecast after upbeat quarterly results
(Reuters) -Abbott Laboratories raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sa...
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
ABBOTT PARK, Ill., Oct. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.
5 Must-See Earnings Charts This Week
What's going on in the economy? These five companies will give us some clues this week.
Abbott Laboratories's Earnings Outlook
Abbott Laboratories(NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement.
Will Abbott Stock Rise After Its Q3 Results?
Abbott is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its e...
Why Earnings Season Could Be Great for Abbott (ABT)
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Solid Growth Stocks Perfect for Retirees
In order to combat the effects of inflation, all retirees need some exposure to growth in their portfolios.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Abbott (ABT) Gains But Lags Market: What You Should Know
In the latest trading session, Abbott (ABT) closed at $117.57, marking a +0.49% move from the previous day.
Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings
Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.
White House pushes back on Abbott's executive order
CNBC's Seema Mody reports on the Biden administration's response to Texas Gov. Abbott's ban of vaccine mandates among employers in the state.
Abbott President & CEO Robert Ford on revolutionizing COVID-19 at-home testing technology
On this episode of Yahoo Finance Presents, Abbott President & CEO Robert Ford, sat down with Yahoo Finance's Anjalee Khemlani to discuss Abbott's upcoming keynote address at CES 2022 and COVID-19 test p...
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Abbott (ABT) closed at $117.91, marking a +1.22% move from the previous day.
Abbott Labs CEO on demand for Covid-19 tests amid delta variant
Abbott Laboratories CEO Robert Ford joins 'TechCheck' to explain why he's confident the company can supply Covid-19 testing to meet demand and whether Abbott is considering investing in AI software.
Abbott (ABT) Gets FDA Nod for Amplatzer Talisman System
The Amplatzer Talisman PFO Occlusion System from Abbott (ABT) is used to treat patients with a patent foramen ovale and are at risk of recurrent ischemic stroke.